China Neurology Clinical Trials Market Report 2022 to 2030

China Neurology Clinical Trials Market Analysis

$ 3999

The China Neurology Clinical Trials market is projected to grow from $420.4 Mn in 2022 to $722.4 Mn by 2030, registering a CAGR of 7% during the forecast period of 2022 - 2030. The market will be driven by the country's increasing incidence of neurological disorders and pharmaceutical firms boosting their investments in R&D. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer, Novartis, Shanghai Green Valley Pharmaceuticals & Jiangsu Hengrui Medicine.

ID: IN10CNCT005 CATEGORY: Clinical Trials GEOGRAPHY: China AUTHOR: Vidhi

Buy Now

China Neurology Clinical Trials Market Executive Summary

The China Neurology Clinical Trials market is projected to grow from $420.4 Mn in 2022 to $722.4 Mn by 2030, registering a CAGR of 7% during the forecast period of 2022 - 2030. According to the survey of the GlobalData Clinical Trials Database, the engagement of Western commercial enterprises in studies conducted in China has significantly increased over the last decade, from over 100 trials per year in 2010 to around 350 in 2021. The overall prevalence of epilepsy in China was 1.68 per 1,000 people. The greatest prevalence of epilepsy was in Heilongjiang (807.8 per 100,000 population), followed by Tibet (Xizang Zizhiqu; 532.4 per 100,000 population), and the lowest in Fujian (20.5 per 100,000 population) and Jiangxi (20.5 per 100,000 population) (20.2 per 100,000 population). According to the 2021 China Alzheimer's Report, 15 Mn individuals aged 60 and above in China have dementia, with 9.8 Mn of them suffering from Alzheimer's.

In China, there are many active clinical studies in neurology. In China, neurological disorders pose an important healthcare burden, and there is increased interest in discovering novel medicines to treat these problems. Phase 2 research of a drug named SHR-1314 for the treatment of multiple sclerosis is one example of a neurology clinical trial in China. This trial is being undertaken by Jiangsu Hengrui Medicine and recruits 380 participants across 30 locations in China. Another example is a Phase 3 trial of Aducanumab, a medication used to treat Alzheimer's disease. The Chinese pharmaceutical firm Shanghai Green Valley Pharmaceuticals is conducting this experiment, which is scheduled to recruit 510 participants across 40 locations in China.

Apart from these particular studies, China is also home to a variety of current clinical trials aimed at researching novel therapies for stroke, Parkinson's disease, and other neurological diseases. In recent years, the Chinese government has made major expenditures in neuroscience research, and a rising number of firms and academic institutions are pursuing research in this sector.

China Neurology Clinical Trials Market

Market Dynamics

Market Growth Drivers

In mainland China, 384 registered drug clinical trials on ischemic stroke were reported between January 1, 2005, and August 1, 2021. A variety of other variables influence the neurology clinical trial industry in China. One major factor is the country's increasing incidence of neurological disorders. As the population ages and lifestyles change, the number of individuals living with illnesses such as Alzheimer's, Parkinson's, and multiple sclerosis has increased significantly. It has resulted in increased investment in clinical research and produced a considerable demand for novel medicines that may address these disorders. The country's big and expanding pharmaceutical sector is another driver of the neurology clinical trial market in China. Chinese pharmaceutical firms are boosting their investments in R&D, with many focusing on discovering novel therapies for neurological illnesses. This has resulted in an increase in the number of clinical trials being undertaken in the nation, which has aided in driving innovation in the sector.

Market Restraints

There are also certain hurdles and restrictions in the Chinese neurology clinical trial market. The regulatory climate is a significant obstacle. China's clinical trial regulatory structure is still changing, and there are concerns regarding the approval application's pace and integrity. Companies may find it challenging to run trials in a timely and cost-effective way as a result of this. Another challenge is the scarcity of competent employees and infrastructure. Although China has made tremendous expenditures in brain research in recent years, there are still gaps in experience and resources that may make conducting high-quality clinical trials challenging for corporations.

Competitive Landscape

Key Players

Pfizer
Novartis
Biogen
Shanghai Green Valley Pharmaceuticals (CHN)
Jiangsu Hengrui Medicine (CHN)
Beigene (CHN)
Innovent Biologics (CHN)
Hutchison MediPharma (CHN)

Notable Insights

February 2023, Jiangsu Hengrui Medical Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. found fibroblast growth factor receptor 2 (FGFR2) inhibitors that have been claimed to be beneficial for cancer therapy.

In November 2019, China's medicines authority announced that Shanghai Green Valley Pharmaceuticals' oligomannate (GV-971) had received conditional clearance to assist enhance cognitive performance in individuals with mild to severe Alzheimer's disease.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Neurology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.